(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

Merck (MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting ...

Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...

An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

We recently published a list of 10 Best Retirement Stocks to Buy According to Hedge Funds. In this article, we are going to ...

The US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...

A little-known Chinese company has made a drug that beats the world's biggest-selling medicine, said a CNN report on ...

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...